

An Uncommon Gastrointestinal Manifestation of Systemic Lupus Erythematosus: Lupus Enteritis

Aimun Raees, Zahabia Sohail and Om Parkash

Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan

ABSTRACT

Systemic Lupus Erythematosus (SLE) is a chronic inflammatory disorder with heterogeneous presentation and clinical course. We present a case of a young female with an atypical presentation of SLE. A young woman with no known prior comorbidities presented with a history of chronic diarrhoea, vomiting, and weight loss, followed by generalized weakness. An extensive workup was done and she was diagnosed with lupus enteritis based on history, laboratory investigations, and imaging findings. She was given pulse therapy to which she responded very well. The case describes the importance of high clinical suspicion and timely intervention as well as adds to the evidence on a rare clinical entity of lupus enteritis.

Key Words: *Systemic lupus erythematosus, Lupus enteritis, Autoimmune disorder, Chronic diarrhoea.*

How to cite this article: Raees A, Sohail Z, Parkash O. An Uncommon Gastrointestinal Manifestation of Systemic Lupus Erythematosus: Lupus Enteritis. *JCPSP Case Rep* 2023; 1:42-44.

INTRODUCTION

Systemic Lupus Erythematosus (SLE) is a common multi-system autoimmune disorder involving a wide spectrum of clinical features. The most frequent presenting symptoms are musculoskeletal or cutaneous, followed by haematological, renal, cardiac, nervous system, and gastrointestinal tract.¹ Gastrointestinal symptoms in SLE were first notified in 1895 and may range from vomiting and abdominal pain to diarrhoea. The magnitude of gastrointestinal involvement is also greatly variable, ranging from hepatitis, pancreatitis, and lupus enteritis (LE) to mesenteric vasculitis.² LE was defined by the British Isles Lupus Assessment Group (BILAG) in 2004 as vasculitis or inflammation of the small bowel, diagnosed based on clinical features supported by suggestive imaging and/or biopsy findings.³ LE may be prevalent in about 0.2-9.7%⁴ of patients diagnosed with SLE but LE presenting as the initial manifestation of the disease is quite rare.⁵ In addition, diagnosing LE without a prior background of SLE can be challenging.

CASE REPORT

A 21-year Asian lady presented to the Emergency Department with complaints of progressive generalised weakness associated with intermittent diarrhoea and vomiting for 6 weeks.

She had been having 7-8 episodes of watery, non-bloody, large-volume stools not associated with fever or abdominal pain. Vomiting was non-projectile, non-biliary, and non-bloody, small volume, exaggerated in the last 4 days. She was initially seen on an outpatient basis and prescribed antibiotics for these symptoms without any improvement in clinical condition. She also reported a weight loss of about 7 kg from baseline weight. Her appetite had been well initially but she was unable to tolerate diet for the past 4 days due to recurrent vomiting. She denied a history of rash, joint pains, hair loss, or oral ulcers. There was no recent travel history. She also denied having any allergies or addiction. There was no family history of tuberculosis or malignancy. Past medical history was significant for a second-trimester abortion of an unidentified cause about 2 months ago. She did not have any previous surgeries or blood transfusions.

On examination, the patient was vitally stable. She was a lean-built lady with vitiligo marks on her legs. She was alert and oriented to time, place, and person. On chest auscultation, decreased air entry was observed in the right lung base. The abdomen was soft and non-tender without any visceromegaly. There was no shifting dullness and gut sounds were audible. Sensory and motor examination was within normal limits.

Laboratory investigations revealed anaemia, severe hypokalemia, hypomagnesemia, hypocalcemia, and metabolic acidosis (Table I). Based on history, clinical examination, and laboratory results, a differential diagnosis of celiac disease, inflammatory bowel disease, and intestinal tuberculosis was made along with protein-losing enteropathy associated with SLE or human immunodeficiency virus (HIV). Further, workup confirmed malabsorption syndrome, so she was planned for an upper and lower gastrointestinal endoscopy. Pre-procedure COVID-19 polymerase chain reaction (PCR) came out positive, so the procedures were postponed.

Correspondence to: Dr. Zahabia Sohail, Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan

E-mail: zahabia.sohail@aku.edu

Received: February 27, 2023; Revised: May 20, 2023;

Accepted: May 28, 2023

DOI: <https://doi.org/10.29271/jcpspcr.2023.42>

Table I: Baseline laboratory investigations of the patient.

Tests	Results	Reference ranges
Hemoglobin	6.0	11-14.5 g/dl
Hematocrit	13.8	34.5-45.4 %
Mean Corpuscular Volume	108.7	78.1-95.3 fL
White blood cells	8.8	4.6-10.8 ×10 ⁹ /L
Neutrophils	86.6	34.9-76.2%
Lymphocytes	7.8	17.5-45%
Platelets	339	154-433×10 ⁹ /L
Amylase	291	28-100 IU/L
Creatinine	1.0	0.6-1.1 mg/dL
Sodium	141	136-145 mmol/L
Potassium	1.5	3.5-5.1 mmol/L
Chloride	108	98-107 mmol/L
Bicarbonate	16.9	20-31 mmol/L
Calcium	7.6	8.6-10.2 mg/dl
Magnesium	1.3	1.6-2.6 mg/dl
Serum glucose	114	80-160 mg/dl
Total bilirubin	3.0	0.1-1.2 mg/dl
Gamma-glutamyl transferase (GGT)	92	<38 IU/L
Alanine Transaminase (ALT)	47	<35 IU/L
Aspartate transaminase (AST)	126	<31 IU/L
Alkaline phosphatase	173	45-129 IU/L
Lipase	512	6-5 IU/L
Prothrombin time (PT)	13.3	9.3-12.8 seconds
Activated partial thromboplastin time (APTT)	20.4	22.9-34.5 second

Table II: Additional laboratory investigations of the patient.

Tests	Results	Reference ranges
Stool analysis	+14 pus cells	
Red blood cell folate	1300.4	280-791 ng/ml
Vitamin B12	>2000	>201 pg/ml Acceptable
Lactate Dehydrogenase (LDH)	715	120-246 IU/L
Erythrocyte Sedimentation Rate (ESR)	47	0-20 mm/1st hour
Reticulocyte count	8.81	0.6-2.4 %
Coombs test	Positive (++++)	
Tissue Transglutaminase Immunoglobulin A (tTg-IgA)	<0.5	Positive: >3.5 U/ml
Tissue Transglutaminase Immunoglobulin (tTg-IgG)	0.72	Positive: >3.5 U/ml
Human Immunodeficiency Virus (HIV)	Non-reactive	
Hepatitis B Surface Antigen (HBsAg)	Non-reactive	
Hepatitis C Virus Antibody (Anti-HCV)	Non-reactive	
Serum albumin	2.5	3.5-5.2 g/dl
Fecal calprotectin	2.5	Negative <43.2 ug/g
Thyroid Stimulating Hormone (TSH)	1.150	Adults: 0.4-4.2 uIU/ml
Anti- Nuclear Antibodies (ANA)	Positive (Homogenous)	
Anti-double-stranded deoxyribonucleic acid antibodies (Anti-dsDNA)	1252	Positive ≥25 IU/ml
Anti-Sjögren Syndrome A (Anti-SSA) (Ro)	1.27	Positive >5.0 U/ml
Anti-Sjögren Syndrome B (Anti-SSB) (La)	0.54	Positive >12.5 U/ml
Smith Antibody (Anti-Sm)	0.81	Positive >5.0 U/ml
Scleroderma Antibodies; anti-topoisomerase (Anti Scl-70)	1.43	Positive >5.0 U/ml
Anti-Cardiolipin Immunoglobulin M	23.41	Positive >7.2 MPL-U/mL
Anti-Cardiolipin Immunoglobulin G	15.40	Positive >14.4 GPL-U/mL
Lupus Anticoagulant screen	51.5	31-44 seconds
Spot Urinary Creatinine	69 mg/dl	-
Spot Urinary Protein	252 mg/dl	-


Figure 1: Computed Tomography (CT) scan (axial view) showing diffuse bowel wall edema and target sign.

Figure 2: Computed Tomography (CT) scan (coronal view) showing diffuse bowel wall oedema and target sign.

She underwent a contrast-enhanced computed tomography (CECT) abdomen which showed diffuse oedema of the stomach, small bowel, and large bowel with a positive target sign. Right-sided pleural effusion and mild ascites were also noted (Figures 1 and 2). Meanwhile, anti-nuclear antibody (ANA), anti-double-stranded deoxyribonucleic acid antibodies (anti-dsDNA), lupus anticoagulant, and anti-cardiolipin antibodies came out positive (Table II). She was diagnosed with LE with associated anti-phospholipid syndrome. She fulfilled 8 of the 17 Systemic Lupus International Collaborating Clinics (SLICC) criteria including serositis, nephritis, hemolytic anaemia, lymphopenia, and presence of ANA, anti-dsDNA, and anti-phospholipid antibodies as well as a positive direct Coombs test. She was started on pulse therapy with intravenous methylprednisolone 1 g per day for 3 days. Her condition improved. She was discharged on oral prednisolone 30 mg twice a day with early follow-up.

DISCUSSION

This case reports an uncommon presenting feature of a commonly occurring disease. It emphasizes that despite being rare, LE is an important differential in patients presenting with gastrointestinal symptoms. It is crucial to identify and treat this condition timely as it may be associated with significant morbidity and mortality; hence, the index of suspicion must be kept high.

SLE is a heterogeneous disease in terms of its clinical presentation, evolution, and prognosis but its manifestation with LE is exceptionally scarce. LE was initially identified in 1980 and due to its heterogeneity and paucity of evidence, it has not been a part of the SLICC criteria for diagnosis of SLE.⁶ LE does not have characteristic clinical features and may present with diverse symptoms such as vomiting, abdominal pain, diarrhoea, ascites, or fever. The pathogenesis of the disease is poorly understood but immune complex deposition along with complement activation seems to be the driving force. The most commonly involved sites are the jejunum and ileum followed by the colon, duodenum, and rectum, respectively.⁷ Endoscopy may not be helpful in such cases due to non-specific findings and the diagnostic yield of histopathology is 6%; hence, CT abdomen with contrast is the gold standard for diagnosis of LE. Demonstration of bowel wall thickness >3 mm (Target sign), mesenteric vessel engorgement (Combs sign), and attenuation of mesenteric fat are the classical features of LE on imaging.⁸ Management includes complete bowel rest and intravenous methylprednisolone as the initial therapy. If this is ineffective, immunosuppression with cyclophosphamide, mycophenolate, or azathioprine should be considered.⁹ Surgical intervention must be considered for resistant cases. Prognosis is usually excellent as the disease is steroid responsive but relapse after initial improvement may be seen in up to 23% of cases.⁹ Involvement of colon and bowel wall diameter >9 mm have been illustrated as risk factors for recurrence. In case of delay in treatment, LE may lead to bowel infarction, bleeding, obstruction, and perforation.⁷ A high fatality rate has been observed with the disease. Recently, Liu *et al.*¹⁰ have established a lupus risk assessment model to predict the development of LE in patients with SLE. Its significance is still unclear; nevertheless, the model might turn out to be useful in the early identification of the disease.

In conclusion, this case highlights LE as the initial manifestation of SLE and the key importance of a CT abdomen in its diagnosis with a remarkable response to steroid therapy.

COMPETING INTEREST:

The authors declared no competing interest.

PATIENT'S CONSENT:

Written informed consent was obtained from the patient.

AUTHORS' CONTRIBUTION:

AR: Conceptualisation and manuscript writing.

ZH: Literature review and proofreading of the manuscript.

OP: Primary physician, diagnosed the case and gave final approval.

REFERENCES

1. Von Feldt JM. Systemic lupus erythematosus: recognizing its various presentations. *Postgrad Med* 1995; **97**(4):79-94.
2. Tian XP, Zhang X: Gastrointestinal involvement in systemic lupus erythematosus: Insight into pathogenesis, diagnosis and treatment. *World J Gastroenterol* 2010; **16**(24): 2971-2977. doi: 10.3748/wjg.v16.i24.2971.
3. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, *et al.* BILAG 2004. Development and initial validation of an updated version of the British Isles lupus assessment group's disease activity index for patients with systemic lupus erythematosus. *Rheumatol (Oxford)* 2005; **44**(7): 902-6. doi: 10.1093/rheumatology/keh624.
4. Brewer BN, Kamen DL. Gastrointestinal and hepatic disease in systemic lupus erythematosus. *Rheum Dis Clin North Am* 2018; **44**(1):165-75. doi: 10.1016/j.rdc.2017.09.011.
5. Lee HA, Shim HG, Seo YH, Choi SJ, Lee BJ, Lee YH, *et al.* Panenteritis as an Initial Presentation of Systemic Lupus Erythematosus. *Korean J Gastroenterol* 2016; **67**(2): 107-11. doi: 10.4166/kjg.2016.67.2.107.
6. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, *et al.* Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012; **64**(8): 2677-2686. doi: 10.1002/art.34473.
7. Janssens P, Arnaud L, Galicier L, Mathian A, Hie M, Sene D, *et al.* Lupus enteritis: From clinical findings to therapeutic management. *Orphanet J Rare Dis* 2013; **8**:67. doi: 10.1186/1750-1172-8-67.
8. Demiselle J, Sayegh J, Cousin M, Olivier A, Augusto JF. An unusual cause of abdominal pain: Lupus enteritis. *Am J Med* 2016; **129**(5): e11-e12. doi: 10.1016/j.amjmed.2016.01.011.
9. Waite L, Morrison E. Severe gastrointestinal involvement in systemic lupus erythematosus treated with rituximab and cyclophosphamide (B-cell depletion therapy) *Lupus* 2007; **16**(10):841-2. doi: 10.1177/0961203307081118.
10. Liu Z, Guo M, Cai Y, Zhao Y, Zeng F, Liu Y. A nomogram to predict the risk of lupus enteritis in systemic lupus erythematosus patients with gastrointestinal involvement. *E Clin Med* 2021; **36**:100900. doi: 10.1016/j.eclinm.2021.100900.

.....